tirzepatide surmount-1 percent weight loss 72 weeks (ZEPBOUND) Approved for Chronic Management in Adults with Obesity ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or The New - SURMOUNT-1: In

Combination approaches The trend toward combining compounds with different mechanisms is accelerating

Read the Medication Guide and Instructions for Use provided by your pharmacist before you start using tirzepatide and each time you get a refill

[22] [3] Segn las guas de la American Diabetes Association (ADA), el monitoreo regular es esencial durante el tratamiento con tirzepatida

Verify any critical information with your healthcare provider.

What tirzepatide does offer: Clinically proven weight reduction that outperforms many existing medications Dual-action mechanism targeting both GIP and GLP-1 receptors for enhanced metabolic effects Convenient once-weekly dosing that improves treatment adherence Dual benefits for those managing both weight and type 2 diabetes The future outlook for tirzepatide appears promising as researchers continue exploring its full potential

Conflict of interest The authors declared that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest